treatment for major depressive disorder

nsi-189 is an experimental, potential antidepressant that is under investigation by neuralstem, inc. for the treatment for major depressive disorder (mdd), as well as for cognitive impairment and neurodegeneration.

a phase ii clinical trial for mdd failed to meet the primary depression endpoint (madrs) in july 2017, although statistically significant improvements have been reported on a number of secondary depression and cognition endpoints.

the compound's activity was discovered using phenotypic screening with a library of 10,269 compounds to identify compounds that promoted neurogenesis in vitro. as of 2016 the target of the compound was unknown but it appeared to promote neurogenesis in

we are raw material vender of potential antidepressant from china.

https://www.tcsindustry.com/pro/nsi_189_free_base_dosage_longecity_modafinil_ecurcumin_solubility.html